Shire in collaboration with MicroHealth on haemophilia monitoring tool
Shire has agreed to collaborate with MicroHealth Inc to support a free and secure monitoring tool for haemophilia A and B patients with inhibitors.
FTSE 100
8,297.71
11:10 07/10/24
FTSE 350
4,575.04
11:10 07/10/24
FTSE All-Share
4,531.94
11:10 07/10/24
Pharmaceuticals & Biotechnology
22,144.65
11:09 07/10/24
Shire Plc
4,690.00p
16:39 08/01/19
The tool was developed in the form of an app by digital healthy company MicroHealth, to help improve haemophilia patient care and outcome through the ability to set reminders, track, store and selectively share personal health data, including photos and bleed alerts, with care team members.
Shire said the collaboration will help the start-up customise the tool with new features and information specifically for the 5-7% of haemophilia patients with inhibitors. Both companies remain independent in this collaboration and Shire does not have access to any patient, caregiver or other third-party data through this collaboration.
Patty Torr, head of US Haematology at Shire, said: "We want to do everything we can to help people manage their haemophilia and to limit the burden of the disease on their everyday lives.
"Shire is a long-standing partner to the haemophilia community and has served haemophilia patients with inhibitors for more than 40 years. Enhancing the existing MicroHealth app with new functionality and resources to address the needs of haemophilia patients with inhibitors is an important innovation for this group of patients.”
Inhibitors are a serious complication in haemophilia patients that can occur when the patient’s immune system prevents standard treatments from working by producing antibodies that inhibit the necessary formation of blood clots.